In a retrospective study evaluating high-dose alkylating agents with autologous hematological stem cell transplantation in 231 advanced breast cancer patients, a small group of 15 BRCA1/2 carriers had a highly favorable survival outcome, in spite of several adverse prognostic factors, such as younger age, visceral disease, more metastatic sites and more TNBC [53]. The gene discussed is BRCA1; the disease is breast carcinoma.